WO2001038322A1 - Inhibitors of histone deacetylase - Google Patents

Inhibitors of histone deacetylase Download PDF

Info

Publication number
WO2001038322A1
WO2001038322A1 PCT/IB2000/001881 IB0001881W WO0138322A1 WO 2001038322 A1 WO2001038322 A1 WO 2001038322A1 IB 0001881 W IB0001881 W IB 0001881W WO 0138322 A1 WO0138322 A1 WO 0138322A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
optionally
inhibitor
group
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001881
Other languages
English (en)
French (fr)
Inventor
Daniel Delorme
Rejean Ruel
Rico Lavoie
Carl Thibault
Elie Abou-Khalil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Priority to AU18768/01A priority Critical patent/AU783504C/en
Priority to EP00981535A priority patent/EP1233958B1/en
Priority to DK00981535.8T priority patent/DK1233958T3/da
Priority to KR1020027006560A priority patent/KR20020070285A/ko
Priority to AT00981535T priority patent/ATE514674T1/de
Priority to CA2391952A priority patent/CA2391952C/en
Priority to MXPA02005196A priority patent/MXPA02005196A/es
Priority to JP2001540085A priority patent/JP2003514904A/ja
Publication of WO2001038322A1 publication Critical patent/WO2001038322A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Definitions

  • L 2 is C,-C 6 saturated alkylene or C,- alkenylene, wherein the alkylene or alkenylene optionally may be substituted, provided that L 2 is not -C(O)-, and wherein one of the carbon atoms of the alkylene optionally may be replaced by a heteroatom moiety selected from the group consisting of O; NR', R' being alkyl, acyl, or hydrogen; S; S(O); or S(0) 2 ;
  • Cy is C 6 -C H aryl, more preferably C 6 -C 10 aryl, and most preferably phenyl or naphthyl, any.of which may be optionally . substituted.
  • Cy is heteroaryl.
  • the heteroaryl group is selected from the group consisting of thienyl, benzothienyl, furyl, benzofuryl, quinolyl, isoquinolyl, and thiazolyl, any of which may be optionally substituted.
  • Cy is selected from the group consisting of phenyl, naphthyl, thienyl, benzothienyl, and quinolyl, any of which may be optionally substituted.
  • the invention provides novel inhibitors of histone deacetylase represented by formula (3):
  • acid V is converted to the corresponding acid chloride, preferably by treatment with oxalic chloride, followed by the addition of a protected hydroxylamine such as O-trimethylsilyl- hydroxylamine in a solvent such as methylene chloride, which then provides the hydroxylamine I upon workup (Method C).
  • a protected hydroxylamine such as O-trimethylsilyl- hydroxylamine in a solvent such as methylene chloride
  • the invention also provides a method for treating or preventing a protozoal disease or infection, comprising administering to an animal in need of such treatment a therapeutically effective amount of a histone deacetylase inhibitor of the invention.
  • the animal is a mammal, more preferably a human.
  • the histone deacetylase inhibitor used according to this embodiment of the invention inhibits a protozoal histone deacetylase to a greater extent than it inhibits mammalian histone deacetylases, particularly human histone deacetylases.
  • such a hybrid oligonucleotide will contain at least three consecutive deoxyribonucleosides and will also contain ribonucleosides, 2'-0-substituted ribonucleosides, or combinations thereof (see e.g., Metelev and Agrawal, U.S. Patent No. 5,652,355).
  • Step 1 80% Yield: Step 2: 81%
  • the combined organic extracts were dried over (MgS0 4 ) then condensed.
  • the crude compound was purified by flash chromatography using Hexane/ acetone (7:3) as solvent mixture. The residue was then dissolved in MeOH (10 mL) then 10-camphorsulfonic acid (CSA, 77 mg, 0.33 mmol) was added. The mixture was stirred 2 h at room temperature then the solvents were evaporated under reduced pressure at room temperature to avoid thermal decomposition.
  • the crude product was purified by flash chromatography using CH 2 CL,/MeOH (9:1) as solvent mixture giving compound 36 (116mg, 55%) as a orange solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/IB2000/001881 1999-11-23 2000-11-22 Inhibitors of histone deacetylase Ceased WO2001038322A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU18768/01A AU783504C (en) 1999-11-23 2000-11-22 Inhibitors of histone deacetylase
EP00981535A EP1233958B1 (en) 1999-11-23 2000-11-22 Inhibitors of histone deacetylase
DK00981535.8T DK1233958T3 (da) 1999-11-23 2000-11-22 Hæmmere af histondeacetylase
KR1020027006560A KR20020070285A (ko) 1999-11-23 2000-11-22 히스톤 디아세틸라제의 억제제
AT00981535T ATE514674T1 (de) 1999-11-23 2000-11-22 Inhibitoren für histone-deacetylase
CA2391952A CA2391952C (en) 1999-11-23 2000-11-22 Inhibitors of histone deacetylase
MXPA02005196A MXPA02005196A (es) 1999-11-23 2000-11-22 Inhibidores de deacetilasa de histona.
JP2001540085A JP2003514904A (ja) 1999-11-23 2000-11-22 ヒストン脱アセチル酵素の抑制剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16703599P 1999-11-23 1999-11-23
US60/167,035 1999-11-23

Publications (1)

Publication Number Publication Date
WO2001038322A1 true WO2001038322A1 (en) 2001-05-31

Family

ID=22605679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001881 Ceased WO2001038322A1 (en) 1999-11-23 2000-11-22 Inhibitors of histone deacetylase

Country Status (11)

Country Link
US (3) US6541661B1 (https=)
EP (2) EP1233958B1 (https=)
JP (2) JP2003514904A (https=)
KR (4) KR20020070285A (https=)
AT (1) ATE514674T1 (https=)
AU (1) AU783504C (https=)
CA (1) CA2391952C (https=)
DK (1) DK1233958T3 (https=)
MX (1) MXPA02005196A (https=)
PT (1) PT1233958E (https=)
WO (1) WO2001038322A1 (https=)

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030879A3 (en) * 2000-09-29 2002-06-27 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2002022577A3 (en) * 2000-09-01 2002-09-06 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2003013484A3 (en) * 2001-08-07 2003-04-17 Hoffmann La Roche N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
WO2003070691A1 (en) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
WO2003076400A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
WO2003076395A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003011851A3 (en) * 2001-06-15 2003-09-18 Hoffmann La Roche Aromatic hydroxamic acid derivatives useful as hdac inhibitors
WO2003076422A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
WO2003076438A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
WO2003076401A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
WO2003087057A1 (en) 2002-04-05 2003-10-23 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
WO2003024448A3 (en) * 2001-09-14 2003-11-13 Methylgene Inc Inhibitors of histone deacetylase
WO2003092686A1 (en) * 2002-04-27 2003-11-13 Astrazeneca Ab Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
WO2004054999A1 (en) * 2002-12-16 2004-07-01 F. Hoffmann-La Roche Ag Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors
WO2004063169A1 (en) * 2003-01-13 2004-07-29 Astellas Pharma Inc. Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
WO2004064824A1 (en) * 2003-01-17 2004-08-05 Italfarmaco Spa Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments
WO2004069823A1 (en) * 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2004071401A3 (en) * 2003-02-11 2004-10-14 Fujisawa Pharmaceutical Co Hydroxamic acid derivatives as histone deacetylase inhibitors (hdca)
WO2004069133A3 (en) * 2003-02-07 2004-11-25 Hoffmann La Roche N-monoacylated o-phenylenediamines as anti -cancer agents
WO2005019174A1 (en) * 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
WO2005030704A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
EP1541549A1 (en) * 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2005075469A1 (en) * 2004-02-04 2005-08-18 Argenta Discovery Limited Thiazolyl-hydroxamic acids and thiadiazolyl-hydroxamic acids, and use thereof for treating diseases associated with histone deacetylase enzymatic activity
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
US6960685B2 (en) 2000-09-29 2005-11-01 Topotarget Uk Limited Carbamic acid compounds comprising an ether linkage as HDAC inhibitors
WO2005087724A3 (en) * 2004-03-11 2005-12-08 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors
WO2006016680A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
WO2006037761A1 (en) * 2004-10-01 2006-04-13 Dac S.R.L. New histone deacetylases inhibitors
WO2006017214A3 (en) * 2004-07-12 2006-06-01 Merck & Co Inc Inhibitors of histone deacetylase
US7071219B2 (en) 2003-02-06 2006-07-04 Hoffmann-La Roche Inc. Mono-acylated o-phenylendiamines derivatives
WO2006093053A1 (ja) 2005-03-02 2006-09-08 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の新規ｐｄマーカー
WO2006105979A1 (en) * 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
WO2006117548A1 (en) 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007039404A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
WO2007091703A1 (en) 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
US7276612B2 (en) 2003-04-07 2007-10-02 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US7282608B2 (en) 2002-10-17 2007-10-16 Methylgene, Inc. Inhibitors of histone deacetylase
EP1501489A4 (en) * 2002-04-15 2007-11-21 Sloan Kettering Inst Cancer COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO2007143822A1 (en) * 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1673349A4 (en) * 2003-09-22 2008-01-23 S Bio Pte Ltd Benzimidazole derivatives: Preparation and pharmaceutical applications
WO2008036046A1 (en) 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2008055068A2 (en) 2006-10-28 2008-05-08 Methylgene Inc. Inhibitors of histone deacetylase
WO2008074132A1 (en) * 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008075757A1 (en) * 2006-12-15 2008-06-26 Astellas Pharma Inc. N-hydroxyacrylamide compounds
US7396944B2 (en) 2004-06-14 2008-07-08 Hoffmann-La Roche Inc. Thiophene derivatives, their manufacture and use as pharmaceutical agents
US7423060B2 (en) 2004-06-14 2008-09-09 Hoffman-La Roche Inc. Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7465719B2 (en) 2003-01-17 2008-12-16 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
US7507828B2 (en) 2003-07-07 2009-03-24 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2009037001A2 (en) 2007-09-19 2009-03-26 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
JP2009521424A (ja) * 2005-12-19 2009-06-04 メチルジーン インコーポレイテッド 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤
US7544695B2 (en) 2005-11-23 2009-06-09 Merck & Co., Inc. Spirocyclic compounds
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
US7569724B2 (en) 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
WO2009095324A1 (en) * 2008-01-29 2009-08-06 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-amide derivatives
EP2100882A1 (en) 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
CN100546980C (zh) * 2003-09-22 2009-10-07 S*Bio私人有限公司 苯并咪唑衍生物:制备方法及医药应用
US7638553B2 (en) 2004-06-14 2009-12-29 Hoffmann-La Roche Inc. Hydroxamates, their manufacture and use as pharmaceutical agents
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US7666868B2 (en) 2005-03-15 2010-02-23 4Sc Ag N-sulphonylpyrroles and their use as histone deacetylase inhibitors
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
US7683185B2 (en) 2002-11-18 2010-03-23 Queen Mary & Westfield College Histone deacetylase inhibitors
EP1771167A4 (en) * 2004-07-19 2010-04-21 Merck Sharp & Dohme Histone deacetylase INHIBITORS:
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2201947A2 (en) 2003-08-26 2010-06-30 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
US7772238B2 (en) 2005-04-20 2010-08-10 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
US7781595B2 (en) 2003-09-22 2010-08-24 S*Bio Pte Ltd. Benzimidazole derivatives: preparation and pharmaceutical applications
WO2010097586A1 (en) 2009-02-27 2010-09-02 Chroma Therapeutics Ltd. Enzyme inhibitors
EP2226072A1 (en) 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
EP2236503A1 (en) 2009-04-03 2010-10-06 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US7834034B2 (en) 2005-04-20 2010-11-16 Merck Sharp & Dohme Corp. Benzothiophene derivatives
EP1874294A4 (en) * 2005-04-20 2010-12-01 Merck Sharp & Dohme BENZOTHIOPHENO HYDROXAMIDIC DERIVATIVES WITH CARBAMATE, UREA, AMID AND SULPHONAMIDE SUBSTITUTIONS
EP2269609A2 (en) 2001-10-16 2011-01-05 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
EP2277387A1 (en) 2009-07-22 2011-01-26 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
EP2295410A1 (en) 2006-10-06 2011-03-16 Chroma Therapeutics Limited HDAC inhibitor
US7977372B2 (en) 2009-02-23 2011-07-12 Hoffmann-La Roche Inc. Ortho aminoamides for the treatment of cancer
US7981874B2 (en) 2006-07-20 2011-07-19 Merck Sharp & Dohme Corp. Phosphorus derivatives as histone deacetylase inhibitors
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US7999000B2 (en) 2008-05-16 2011-08-16 Hoffmann-La Roche Inc. N-(2-amino-phenyl)-acrylamides
US8008344B2 (en) 2007-09-14 2011-08-30 NatureWise Biotech and Medicals Corporation Compounds for the inhibition of histone deacetylase
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US8093295B2 (en) 2005-05-20 2012-01-10 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing the same
US8110577B2 (en) 2006-10-19 2012-02-07 Queen Mary & Westfield College Histone deacetylase inhibitors
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8119685B2 (en) 2006-04-26 2012-02-21 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US8188138B2 (en) 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
US8207202B2 (en) 2005-10-19 2012-06-26 Astrazeneca Ab Benzamide compounds useful as histone deacetylase inhibitors
CN102548975A (zh) * 2009-07-07 2012-07-04 安瑟生物科技私人有限公司 组蛋白去乙酰化酶抑制剂
US8242175B2 (en) 2004-10-01 2012-08-14 Dac S.R.L. Class of histone deacetylase inhibitors
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
WO2012109527A3 (en) * 2011-02-10 2012-10-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US8318808B2 (en) 2003-12-02 2012-11-27 The Ohio State University Research Foundation Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
EP2532657A2 (en) 2008-10-14 2012-12-12 Sunshine Lake Pharma Co., Ltd Compounds and methods of use
WO2012112447A3 (en) * 2011-02-14 2012-12-27 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
US8450525B2 (en) 2007-10-22 2013-05-28 Orchid Chemicals & Pharmaceuticals Limited Histone deacetylase inhibitors
US8461189B2 (en) 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
US8563615B2 (en) 2009-10-30 2013-10-22 Massachusetts Institute Of Technology Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
WO2014022117A1 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US8796330B2 (en) 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2014130375A1 (en) 2013-02-21 2014-08-28 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators
EP2680694A4 (en) * 2011-02-28 2014-09-03 Repligen Corp Histone deacetylase INHIBITORS
WO2014138989A1 (en) * 2013-03-15 2014-09-18 Methylgene Inc. Method and intermediates for the synthesis of hydroxamic acid compounds
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
US9128096B2 (en) 2007-01-30 2015-09-08 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US9133104B2 (en) 2005-05-05 2015-09-15 Chroma Therapeutics Ltd. Enzyme inhibitors
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
CN105237444A (zh) * 2015-09-24 2016-01-13 沈阳药科大学 异羟肟酸类化合物及其制备方法和用途
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9403032B2 (en) 2009-04-17 2016-08-02 Pharmacyclics Llc Formulations of histone deacetylase inhibitor and uses therof
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
WO2017067447A1 (en) 2015-10-19 2017-04-27 Sunshine Lake Pharma Co., Ltd. A salt of egfr inhibitor, crystalline form and uses thereof
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
EP3299019A1 (en) 2012-11-14 2018-03-28 Calitor Sciences, LLC Heteroaromatic compounds as pi3 kinase modulators and methods of use
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN109563046A (zh) * 2016-05-16 2019-04-02 Dcb-美国有限责任公司 组蛋白去乙酰酶6抑制剂及其用途
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3484858A4 (en) * 2016-06-21 2020-02-26 The University of Melbourne HIV LATENCY ACTIVATORS
US10626092B2 (en) 2016-05-02 2020-04-21 Mei Pharma, Inc. Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereof
CN111072582A (zh) * 2018-10-18 2020-04-28 中国药科大学 一种n－羟基芳杂环－2－甲酰胺化合物及其制备方法和用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022018462A1 (en) * 2020-07-24 2022-01-27 University Of Newcastle Upon Tyne Catechol based derivatives for use in the prevention of dna damage
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
AU2001248701A1 (en) * 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7276608B2 (en) * 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
WO2005034880A2 (en) * 2003-10-09 2005-04-21 Aton Pharma, Inc. Thiophene and benzothiophene hydroxamic acid derivatives
EP1697538A1 (en) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Method for identifying histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005061448A1 (en) * 2003-12-24 2005-07-07 Monash University Compositions and methods for treating vascular conditions
US20050197336A1 (en) * 2004-03-08 2005-09-08 Miikana Therapeutics Corporation Inhibitors of histone deacetylase
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
ITMI20060621A1 (it) * 2006-03-31 2007-10-01 Dac Srl Nuova classe di inibitori delle istone deacetilasi
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
AU2006228957A1 (en) * 2005-04-01 2006-10-05 Methylgene Inc. Inhibitors of histone deacetylase
CN101189003B (zh) 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2007214458C1 (en) * 2006-02-14 2012-12-06 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2654540C (en) * 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2124916A1 (en) * 2007-02-27 2009-12-02 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
CA2683557C (en) * 2007-04-09 2016-10-18 Methylgene Inc. Inhibitors of histone deacetylase
US7737175B2 (en) * 2007-06-01 2010-06-15 Duke University Methods and compositions for regulating HDAC4 activity
JP2010540426A (ja) * 2007-09-25 2010-12-24 トポターゲット ユーケー リミテッド 特定のヒドロキサム酸化合物の合成方法
CN101417967A (zh) * 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
US20110044952A1 (en) * 2007-11-27 2011-02-24 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
AU2009220942B2 (en) * 2008-03-07 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Methods of treatment employing prolonged continuous infusion of Belinostat
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
RU2515611C2 (ru) * 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
EP2349985A2 (en) 2008-10-15 2011-08-03 Generics [UK] Limited Process for the preparation of vorinostat
JP2012509929A (ja) 2008-11-26 2012-04-26 ジェネリクス・（ユーケー）・リミテッド 多型
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9096518B2 (en) * 2009-06-22 2015-08-04 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
KR200454001Y1 (ko) * 2009-11-03 2011-06-10 주식회사 한길테크 수위조절장치
WO2011106632A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8546588B2 (en) * 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011130163A1 (en) 2010-04-12 2011-10-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8471026B2 (en) 2010-08-26 2013-06-25 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
CN112920181A (zh) * 2021-01-29 2021-06-08 中国医科大学 N-(5-苯基-1,3,4-噻二唑-2-基)苯甲酰胺类化合物
CN115304513A (zh) * 2022-08-25 2022-11-08 湖北科技学院 具有抗炎活性的查尔酮类衍生物及其合成方法和应用
CN121248445A (zh) * 2025-09-29 2026-01-02 亳州学院 一种萘型查尔酮类化合物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5436229A (en) * 1977-08-25 1979-03-16 Hokuriku Pharmaceutical Substituted acetohydroxam derivative
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
JPH11302173A (ja) * 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB239863A (en) 1924-09-10 1925-11-19 Rachlis Dupin & Cie Sa Improvements in speed-changing system for cycle vehicles
US2279560A (en) 1940-05-08 1942-04-14 Du Pont Viscous hydrocarbon oil
US2279973A (en) 1940-05-08 1942-04-14 Du Pont Stabilization of organic substances
DE855866C (de) * 1950-12-16 1952-11-17 Schering Ag Verfahren zur Herstellung von o-Oxybenzhydroxamsaeuren
US2754286A (en) 1951-10-15 1956-07-10 Du Pont Aldehydes and their acetals
US4173577A (en) * 1970-09-09 1979-11-06 Ciba-Geigy Corporation Phenylacetohydroxamic acids
US4035376A (en) 1972-10-24 1977-07-12 Janssen Pharmaceutica N.V. Aroyl-substituted phenylacetic acid derivatives
BE826017R (fr) 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
JPS5651144A (en) 1979-10-03 1981-05-08 Nippon Telegr & Teleph Corp <Ntt> Station address control system
JPS5651441A (en) 1979-10-05 1981-05-09 Nissan Chem Ind Ltd O- n-allyl-2,6-dichloroanilino phenylacetic acid derivative and its preparation
GB8531839D0 (en) 1985-12-30 1986-02-05 Wellcome Found Aryl derivatives
WO1986005779A1 (en) 1985-04-03 1986-10-09 Yamanouchi Pharmaceutical Co., Ltd. Phenylene derivatives
US4792560A (en) 1985-04-03 1988-12-20 Rorer Pharmaceutical Corporation Quinoline hydroxamates and their use as modulators of arachidonic acid metabolic pathways
GB8820185D0 (en) 1988-08-25 1988-09-28 Wellcome Found New medical use
US5364944A (en) 1989-10-27 1994-11-15 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole- alkanoic acid compounds
US5218124A (en) 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5028629A (en) 1990-03-28 1991-07-02 Eli Lilly And Company 5-Lipoxygenase inhibitors
JPH04217950A (ja) * 1990-03-28 1992-08-07 Asahi Chem Ind Co Ltd ヒドロキサム酸誘導体および酵素阻害剤ならびに抗潰瘍剤
FR2677984B1 (fr) 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
KR100236806B1 (ko) 1991-12-10 2000-01-15 시오노 요시히코 방향족 설폰아미드계 하이드록삼산 유도체
AT397908B (de) 1991-12-23 1994-08-25 Zengerer Johannes Staubsauger
MY128102A (en) * 1993-02-17 2007-01-31 Chugai Pharmaceutical Co Ltd Indolin-2-one-derivatives
US5538777A (en) 1993-09-01 1996-07-23 Marley Mouldings Inc. Triple extruded frame profiles
WO1995013264A1 (en) 1993-11-08 1995-05-18 Terumo Kabushiki Kaisha Hydroxamic acid derivative and medicinal preparation containing the same
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
WO1997011366A1 (en) 1995-09-20 1997-03-27 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US5702811A (en) * 1995-10-20 1997-12-30 Ho; Kwok-Lun High performance abrasive articles containing abrasive grains and nonabrasive composite grains
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
GB9609794D0 (en) 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU731737B2 (en) 1996-10-16 2001-04-05 Wyeth Holdings Corporation The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO1998025949A1 (en) * 1996-12-09 1998-06-18 Proscript, Inc. Substituted 5-amino-1,3,4-thiadiazole-2-thiones
JPH10182583A (ja) * 1996-12-25 1998-07-07 Mitsui Chem Inc 新規ヒドロキサム酸誘導体
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2319680C (en) 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5776888A (en) 1997-02-07 1998-07-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6380258B2 (en) * 1997-03-04 2002-04-30 G. D. Searle, L.L.C. Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
BR9813554A (pt) 1997-12-12 2001-07-24 Fuji Yakuhin Kogyo Kk Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase
US6455522B1 (en) * 1998-02-11 2002-09-24 Bristol-Myers Squibb Pharma Company Cyclic sulfonamide derivatives as metalloproteinase inhibitors
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
WO2000056704A1 (en) * 1999-03-22 2000-09-28 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
HK1045501A1 (zh) 1999-05-12 2002-11-29 G.D. Searle & Co. 作为基质金属蛋白酶抑制剂的异羟肟酸衍生物
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
AU3263201A (en) 1999-11-24 2001-06-04 University Of Hawaii Beam-steerer using reconfigurable pbg ground plane
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2423744C (en) * 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US20040072770A1 (en) 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5436229A (en) * 1977-08-25 1979-03-16 Hokuriku Pharmaceutical Substituted acetohydroxam derivative
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
WO1998055449A1 (en) * 1997-06-06 1998-12-10 The University Of Queensland Hydroxamic acid compounds having anticancer and anti-parasitic properties
JPH11302173A (ja) * 1998-04-16 1999-11-02 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害剤

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CANCER RES. 1999 59(17), 4392-99 *
CHEMICAL ABSTRACTS, vol. 131, no. 24, 13 December 1999, Columbus, Ohio, US; abstract no. 317417, GLICK, RICHARD D. ET AL.: "Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma" XP002162156 *
CHEMICAL ABSTRACTS, vol. 131, no. 8, 23 August 1999, Columbus, Ohio, US; abstract no. 97120, KIM, YOUNG BAE ET AL: "Oxamflatin is a novel antitumor compounds that inhibits mammalian histone deacetylase" XP002162155 *
CHEMICAL ABSTRACTS, vol. 91, no. 13, 24 September 1979, Columbus, Ohio, US; abstract no. 107818, KATO HIDEO ET AL.: "Substituted acetohydroxamic acid derivatives" XP002162154 *
DATABASE BEILSTEIN Beilstein Informationssysteme GmbH; XP002162157 *
DATABASE BEILSTEIN Beilsteininformationssysteme GmbH; XP002162158 *
DATABASE BEILSTEIN Beilsteininformationssysteme GmbH; XP002162159 *
DATABASE BEILSTEIN Beilsteininformationssysteme GmbH; XP002162160 *
DATABASE BEILSTEIN Belstein Informationssysteme GmbH; XP002162161 *
English translation of JP-11302173 *
MANFRED JUNG ET AL.: "Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell differentiation", J. MED. CHEM., vol. 42, no. 22, 4 November 1999 (1999-11-04), pages 4669 - 79, XP002144226 *
ONCOGENE (1999), 18(15), 2461-70 *

Cited By (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870399A1 (en) * 2000-09-01 2007-12-26 Novartis AG Hydroxamate derivatives useful as deacetylase inhibitors
WO2002022577A3 (en) * 2000-09-01 2002-09-06 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
US7067551B2 (en) 2000-09-01 2006-06-27 Novartis Ag Deacetylase inhibitors
US6552065B2 (en) 2000-09-01 2003-04-22 Novartis Ag Deacetylase inhibitors
CZ302707B6 (cs) * 2000-09-01 2011-09-14 Novartis Ag N-Hydroxylované deriváty amidu a farmaceutické prostredky, které je obsahují
EP2292593A2 (en) 2000-09-29 2011-03-09 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US6960685B2 (en) 2000-09-29 2005-11-01 Topotarget Uk Limited Carbamic acid compounds comprising an ether linkage as HDAC inhibitors
WO2002030879A3 (en) * 2000-09-29 2002-06-27 Prolifix Ltd Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
US7407988B2 (en) 2000-09-29 2008-08-05 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US7569724B2 (en) 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US7183298B2 (en) 2000-09-29 2007-02-27 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US7880020B2 (en) 2000-09-29 2011-02-01 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
US6888027B2 (en) 2000-09-29 2005-05-03 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US7557140B2 (en) 2000-09-29 2009-07-07 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US9486421B2 (en) 2001-03-27 2016-11-08 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
AU2002355626B2 (en) * 2001-06-15 2008-09-25 F. Hoffmann-La Roche Ag Aromatic hydroxamic acid derivatives useful as HDAC inhibitors
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
WO2003011851A3 (en) * 2001-06-15 2003-09-18 Hoffmann La Roche Aromatic hydroxamic acid derivatives useful as hdac inhibitors
KR100910958B1 (ko) 2001-06-15 2009-08-05 에프. 호프만-라 로슈 아게 Ｈｄａｃ 억제제로 유용한 방향족 히드록삼산 유도체
US6869953B2 (en) 2001-08-07 2005-03-22 Hoffman-La Roche Inc. N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents
WO2003013484A3 (en) * 2001-08-07 2003-04-17 Hoffmann La Roche N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
US6946462B2 (en) 2001-08-07 2005-09-20 Hoffmann-La Roche Inc. N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents
US7838520B2 (en) 2001-09-14 2010-11-23 Methylgene, Inc. Inhibitors of histone deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
JP2005255683A (ja) * 2001-09-14 2005-09-22 Methylgene Inc ヒストンデアセチラーゼの阻害剤
US7595343B2 (en) 2001-09-14 2009-09-29 Methylgene, Inc. Inhibitors of histone deacetylase
CN1578663B (zh) * 2001-09-14 2011-05-25 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
AU2002327627B2 (en) * 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003024448A3 (en) * 2001-09-14 2003-11-13 Methylgene Inc Inhibitors of histone deacetylase
US6946441B2 (en) 2001-09-27 2005-09-20 Regents of the University of Colorado, A Body Corporation Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US7879865B2 (en) 2001-10-16 2011-02-01 Sloan-Kettering Institute For Cancer Research Treatment of cancer of the brain using histone deacetylase inhibitors
EP2269609A2 (en) 2001-10-16 2011-01-05 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
WO2003070691A1 (en) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
US8101663B2 (en) 2002-03-04 2012-01-24 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7732490B2 (en) 2002-03-04 2010-06-08 Merck Hdac Research, Llc Methods of treating cancer
EP2322160A1 (en) 2002-03-04 2011-05-18 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US7375137B2 (en) 2002-03-04 2008-05-20 Merck Hdac Research, Llc Methods of treating cancer with HDAC inhibitors
US7851509B2 (en) 2002-03-04 2010-12-14 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
EP2082737A2 (en) 2002-03-04 2009-07-29 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US7399787B2 (en) 2002-03-04 2008-07-15 Merck Hdac Research, Llc Methods of treating cancer with HDAC inhibitors
US7652069B2 (en) 2002-03-04 2010-01-26 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
EP2266552A2 (en) 2002-03-04 2010-12-29 Merck HDAC Research, LLC Methods of inducing terminal differentiation
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US8067472B2 (en) 2002-03-04 2011-11-29 Merck Hdac Research, Llc Methods of treating Hodgkin's and non-Hodgkin's lymphoma
EP1487426A4 (en) * 2002-03-04 2007-09-19 Aton Pharma Inc PROCESS FOR INTRODUCING TERMINAL DIFFERENTIATION
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US7847122B2 (en) 2002-03-04 2010-12-07 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7566535B2 (en) 2002-03-07 2009-07-28 University Of Delaware Enhanced oligonucleotide-mediated nucleic acid sequence alteration
US7816363B2 (en) 2002-03-13 2010-10-19 Janssen Pharmaceutica, N.V. Inhibitors of histone deacetylase
JP2005525379A (ja) * 2002-03-13 2005-08-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤
AU2003212335B8 (en) * 2002-03-13 2009-04-23 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US7501417B2 (en) * 2002-03-13 2009-03-10 Janssen Pharmaceutica, N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US7615553B2 (en) 2002-03-13 2009-11-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
US7592450B2 (en) 2002-03-13 2009-09-22 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as inhibitors of histone deacetylase
CN101007803B (zh) * 2002-03-13 2012-03-21 詹森药业有限公司 用作新的组蛋白脱乙酰化酶抑制剂的哌嗪基、哌啶基和吗啉基衍生物
CN100445276C (zh) * 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
US8268833B2 (en) 2002-03-13 2012-09-18 Janssen Pharmaceutica, N.V. Inhibitors of histone deacetylase
US7541369B2 (en) 2002-03-13 2009-06-02 Janssen Pharmaceutica, Nv Amino-derivatives as novel inhibitors of histone deacetylase
US8114999B2 (en) 2002-03-13 2012-02-14 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US7446109B2 (en) 2002-03-13 2008-11-04 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003076400A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
EA007908B1 (ru) * 2002-03-13 2007-02-27 Янссен Фармацевтика Н.В. Карбониламинопроизводные как новые ингибиторы гистондеацетилазы
US8097611B2 (en) 2002-03-13 2012-01-17 Janssen Pharmaceutica, N.V. Sulfonyl-derivatives as novel or histone deacetylase
CN1305850C (zh) * 2002-03-13 2007-03-21 詹森药业有限公司 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
US8343988B2 (en) 2002-03-13 2013-01-01 Janssen Pharmaceutica, N.V Inhibitors of histone deacetylase
JP4836405B2 (ja) * 2002-03-13 2011-12-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのアミノカルボニル誘導体
US7205304B2 (en) 2002-03-13 2007-04-17 Janssen Pharmaceutica N.V. Sulfonyl-Derivatives as novel inhibitors of histone deacetylase
US9150560B2 (en) 2002-03-13 2015-10-06 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
EA008245B1 (ru) * 2002-03-13 2007-04-27 Янссен Фармацевтика Н.В. Ингибиторы гистондеацетилазы
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003076401A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US7704998B2 (en) 2002-03-13 2010-04-27 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors or histone deacetylase
WO2003076430A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US8394831B2 (en) 2002-03-13 2013-03-12 Janssen Pharmaceutica, N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003076438A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
JP2005519950A (ja) * 2002-03-13 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体
JP2005523907A (ja) * 2002-03-13 2005-08-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのアミノカルボニル誘導体
CN100519527C (zh) * 2002-03-13 2009-07-29 詹森药业有限公司 组织蛋白去乙酰酶抑制剂
CN1642551B (zh) * 2002-03-13 2011-09-14 詹森药业有限公司 组蛋白脱乙酰基酶抑制剂
WO2003076421A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
JP2005526763A (ja) * 2002-03-13 2005-09-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体
US8865720B2 (en) 2002-03-13 2014-10-21 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase
WO2003075929A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
US9556161B2 (en) 2002-03-13 2017-01-31 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
AU2003218737B2 (en) * 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
JP2005525380A (ja) * 2002-03-13 2005-08-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのスルホニル誘導体
US7709487B2 (en) 2002-03-13 2010-05-04 Janssen Pharmaceutica Nv Sulfonyl-derivatives as novel inhibitors of histone deacetylase
US8455498B2 (en) 2002-03-13 2013-06-04 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
US8501737B2 (en) 2002-03-13 2013-08-06 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
US9533979B2 (en) 2002-03-13 2017-01-03 Janssen Pharmaceutica Nv Amino-derivatives as novel inhibitors of histone deacetylase
WO2003076422A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
US8557825B2 (en) 2002-03-13 2013-10-15 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
US7767679B2 (en) 2002-03-13 2010-08-03 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
CN100396679C (zh) * 2002-03-13 2008-06-25 詹森药业有限公司 用作组蛋白脱乙酰化酶抑制剂的哌嗪基、哌啶基和吗啉基衍生物
WO2003076395A1 (en) * 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP2005527556A (ja) * 2002-04-03 2005-09-15 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
US7629343B2 (en) 2002-04-03 2009-12-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
US7981895B2 (en) 2002-04-03 2011-07-19 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
US8247562B2 (en) 2002-04-05 2012-08-21 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
KR101066508B1 (ko) * 2002-04-05 2011-09-21 아스트라제네카 아베 히스톤 디아세틸라제 저해제로 유용한 벤즈아미드 유도체
WO2003087057A1 (en) 2002-04-05 2003-10-23 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
RU2376287C2 (ru) * 2002-04-05 2009-12-20 Астразенека Аб Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
US7495022B2 (en) 2002-04-11 2009-02-24 Sk Chemicals Co., Ltd. α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
EP1501489A4 (en) * 2002-04-15 2007-11-21 Sloan Kettering Inst Cancer COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO2003092686A1 (en) * 2002-04-27 2003-11-13 Astrazeneca Ab Inhibitors of histone deacetylase
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7399884B2 (en) 2002-10-08 2008-07-15 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7282608B2 (en) 2002-10-17 2007-10-16 Methylgene, Inc. Inhibitors of histone deacetylase
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7683185B2 (en) 2002-11-18 2010-03-23 Queen Mary & Westfield College Histone deacetylase inhibitors
CN100391954C (zh) * 2002-12-16 2008-06-04 霍夫曼-拉罗奇有限公司 噻吩异羟肟酸衍生物的对映异构体及其作为hdac抑制剂的应用
KR100781929B1 (ko) * 2002-12-16 2007-12-04 에프. 호프만-라 로슈 아게 티오펜 히드록삼산 유도체들의 거울상 이성질체 및ｈｄａｃ 저해제로서의 이들의 용도
WO2004054999A1 (en) * 2002-12-16 2004-07-01 F. Hoffmann-La Roche Ag Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
WO2004063169A1 (en) * 2003-01-13 2004-07-29 Astellas Pharma Inc. Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
US8227515B2 (en) 2003-01-17 2012-07-24 Italfarmaco S.P.A. Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments
US7465719B2 (en) 2003-01-17 2008-12-16 Topotarget Uk Limited Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors
WO2004064824A1 (en) * 2003-01-17 2004-08-05 Italfarmaco Spa Use of hydroxamic acid derivatives for the preparation of anti-tumour medicaments
AU2004210016B2 (en) * 2003-02-04 2009-10-08 Methylgene Inc. Inhibitors of histone deacetylase
WO2004069823A1 (en) * 2003-02-04 2004-08-19 Methylgene, Inc. Inhibitors of histone deacetylase
KR100893804B1 (ko) 2003-02-04 2009-04-20 메틸진 인크. 히스톤 데아세틸라아제의 억제제
US7071219B2 (en) 2003-02-06 2006-07-04 Hoffmann-La Roche Inc. Mono-acylated o-phenylendiamines derivatives
US7501451B2 (en) 2003-02-06 2009-03-10 Hoffmann-La Roche Inc. Mono-acylated o-phenylendiamines derivatives
CN100383138C (zh) * 2003-02-07 2008-04-23 霍夫曼-拉罗奇有限公司 N-单乙酰代邻苯二胺类、其稠合杂环衍生物及其作为制备药剂的应用
WO2004069133A3 (en) * 2003-02-07 2004-11-25 Hoffmann La Roche N-monoacylated o-phenylenediamines as anti -cancer agents
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2004071401A3 (en) * 2003-02-11 2004-10-14 Fujisawa Pharmaceutical Co Hydroxamic acid derivatives as histone deacetylase inhibitors (hdca)
WO2004076386A2 (en) 2003-02-25 2004-09-10 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
WO2004076386A3 (en) * 2003-02-25 2004-10-28 Topotarget Uk Ltd Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
US8071620B2 (en) 2003-02-25 2011-12-06 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
JP2006518730A (ja) * 2003-02-25 2006-08-17 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むカルバミン酸化合物
AU2004215624B2 (en) * 2003-02-25 2011-06-02 Topotarget Uk Limited Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7482466B2 (en) 2003-04-07 2009-01-27 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US8779171B2 (en) 2003-04-07 2014-07-15 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US8026371B2 (en) 2003-04-07 2011-09-27 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US7276612B2 (en) 2003-04-07 2007-10-02 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US7517988B2 (en) 2003-04-07 2009-04-14 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US8389570B2 (en) 2003-04-07 2013-03-05 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US9186347B1 (en) 2003-04-07 2015-11-17 Pharmacyclics Llc Hydroxamates as therapeutic agents
US7834054B2 (en) 2003-04-07 2010-11-16 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US7420089B2 (en) 2003-04-07 2008-09-02 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
US8067600B2 (en) 2003-07-07 2011-11-29 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US7507828B2 (en) 2003-07-07 2009-03-24 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
US8748463B2 (en) 2003-07-07 2014-06-10 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005019174A1 (en) * 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
US7368572B2 (en) 2003-08-20 2008-05-06 Pharmacyclics, Inc. Acetylene derivatives as inhibitors of histone deacetylase
EP2201947A2 (en) 2003-08-26 2010-06-30 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
EP2226072A1 (en) 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
US7781595B2 (en) 2003-09-22 2010-08-24 S*Bio Pte Ltd. Benzimidazole derivatives: preparation and pharmaceutical applications
US8551988B2 (en) 2003-09-22 2013-10-08 Mei Pharma, Inc. Benzimidazole derivatives: preparation and pharmaceutical applications
US9402829B2 (en) 2003-09-22 2016-08-02 Mei Pharma, Inc. Benzimidazole derivatives: preparation and pharmaceutical applications
US9024029B2 (en) 2003-09-22 2015-05-05 Mei Pharma, Inc. Benzimidazole derivatives: preparation and pharmaceutical applications
US10736881B2 (en) 2003-09-22 2020-08-11 Mei Pharma, Inc. Benzimidazole derivatives: preparation and pharmaceutical applications
US10201527B2 (en) 2003-09-22 2019-02-12 Mei Pharma, Inc. Benzimidazole derivatives: preparation and pharmaceutical applications
US9717713B2 (en) 2003-09-22 2017-08-01 Mei Pharma, Inc. Benzimidazole derivatives: preparation and pharmaceutical applications
CN100546980C (zh) * 2003-09-22 2009-10-07 S*Bio私人有限公司 苯并咪唑衍生物:制备方法及医药应用
EP1673349A4 (en) * 2003-09-22 2008-01-23 S Bio Pte Ltd Benzimidazole derivatives: Preparation and pharmaceutical applications
WO2005030705A1 (en) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
JP2008094847A (ja) * 2003-09-24 2008-04-24 Methylgene Inc ヒストンデアセチラーゼの阻害剤
WO2005030704A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
US7868205B2 (en) 2003-09-24 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
JP2007506785A (ja) * 2003-09-24 2007-03-22 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
US8318808B2 (en) 2003-12-02 2012-11-27 The Ohio State University Research Foundation Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
US9115090B2 (en) 2003-12-02 2015-08-25 The Ohio State University Research Foundation Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
EP1541549A1 (en) * 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US7923579B2 (en) 2003-12-12 2011-04-12 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzamide derivatives, compositions and methods
WO2005058803A1 (en) * 2003-12-12 2005-06-30 Exonhit Therapeutics Sa Tricyclic hydroxamate and benzamide derivatives, compositions and methods
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2005075469A1 (en) * 2004-02-04 2005-08-18 Argenta Discovery Limited Thiazolyl-hydroxamic acids and thiadiazolyl-hydroxamic acids, and use thereof for treating diseases associated with histone deacetylase enzymatic activity
EA012451B1 (ru) * 2004-03-11 2009-10-30 4Сц Аг Новые амидозамещённые гидрокси-6-фенилфенантридины
WO2005087724A3 (en) * 2004-03-11 2005-12-08 Altana Pharma Ag Sulphonylpyrroles as hdac inhibitors
EP2272827A1 (en) 2004-03-11 2011-01-12 4Sc Ag Sulphonylpyrroles as hdac inhibitors
KR101130556B1 (ko) 2004-03-11 2012-03-30 4에스체 악티엔게젤샤프트 Ｈｄａｃ 억제제로서의 설포닐피롤
AU2005221834B2 (en) * 2004-03-11 2010-09-30 4Sc Ag Sulphonylpyrroles as HDAC inhibitors
US8067615B2 (en) 2004-03-11 2011-11-29 4Sc Ag Sulphonylpyrroles
US8399505B2 (en) 2004-03-11 2013-03-19 4Sc Ag Sulfonylpyrroles
US8969401B2 (en) 2004-03-11 2015-03-03 4Sc Ag Sulfonylpyrroles
NO337457B1 (no) * 2004-03-11 2016-04-18 4Sc Ag Nye amido-substituerte hydroksy-6-fenylfenantridiner
US7842820B2 (en) 2004-03-11 2010-11-30 4Sc Ag Sulfonylpyrroles
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
US8088805B2 (en) 2004-03-26 2012-01-03 Methylgene Inc. Inhibitors of histone deacetylase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
US7638553B2 (en) 2004-06-14 2009-12-29 Hoffmann-La Roche Inc. Hydroxamates, their manufacture and use as pharmaceutical agents
US7423060B2 (en) 2004-06-14 2008-09-09 Hoffman-La Roche Inc. Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors
US7396944B2 (en) 2004-06-14 2008-07-08 Hoffmann-La Roche Inc. Thiophene derivatives, their manufacture and use as pharmaceutical agents
WO2006017214A3 (en) * 2004-07-12 2006-06-01 Merck & Co Inc Inhibitors of histone deacetylase
EP1771167A4 (en) * 2004-07-19 2010-04-21 Merck Sharp & Dohme Histone deacetylase INHIBITORS:
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
US9636341B2 (en) 2004-07-28 2017-05-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006016680A1 (en) * 2004-08-09 2006-02-16 Astellas Pharma Inc. Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
US8058273B2 (en) 2004-10-01 2011-11-15 Dac S.R.L. Histone deacetylases inhibitors
US7803800B2 (en) 2004-10-01 2010-09-28 Dac S.R.L. Histone deacetylases inhibitors
US8242175B2 (en) 2004-10-01 2012-08-14 Dac S.R.L. Class of histone deacetylase inhibitors
WO2006037761A1 (en) * 2004-10-01 2006-04-13 Dac S.R.L. New histone deacetylases inhibitors
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7772245B2 (en) 2005-02-14 2010-08-10 Miikana Therapeutics, Inc. Inhibitors of histone deacetylase
WO2006093053A1 (ja) 2005-03-02 2006-09-08 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の新規ｐｄマーカー
EP1855111A4 (en) * 2005-03-02 2008-10-01 Astellas Pharma Inc NEW PD MARKER FOR HISTONE DEACETYLASE INHIBITOR
CN101137623B (zh) * 2005-03-15 2013-03-27 奈科明有限责任公司 N-磺酰基吡咯及其作为组蛋白脱乙酰酶抑制剂的用途
US8815855B2 (en) 2005-03-15 2014-08-26 4Sc Ag N-sulphonylpyrroles and their use as histone deacetylase inhibitors
US7666868B2 (en) 2005-03-15 2010-02-23 4Sc Ag N-sulphonylpyrroles and their use as histone deacetylase inhibitors
US8901149B2 (en) 2005-03-21 2014-12-02 Mei Pharma, Inc. Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
US9266882B2 (en) 2005-03-21 2016-02-23 Mei Pharma, Inc. Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
US8648092B2 (en) 2005-03-21 2014-02-11 MEI Pharma Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
AU2006232773B2 (en) * 2005-04-07 2012-04-12 4Sc Ag Sulfonylpyrroles as histone deacetylase inhibitors
WO2006105979A1 (en) * 2005-04-07 2006-10-12 Nycomed Gmbh Sulfonylpyrroles as histone deacetylase inhibitors
US7872024B2 (en) 2005-04-20 2011-01-18 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
US7772238B2 (en) 2005-04-20 2010-08-10 Merck Sharp & Dohme Corp. Benzothiophene hydroxamic acid derivatives
US7834034B2 (en) 2005-04-20 2010-11-16 Merck Sharp & Dohme Corp. Benzothiophene derivatives
EP1874294A4 (en) * 2005-04-20 2010-12-01 Merck Sharp & Dohme BENZOTHIOPHENO HYDROXAMIDIC DERIVATIVES WITH CARBAMATE, UREA, AMID AND SULPHONAMIDE SUBSTITUTIONS
WO2006117548A1 (en) 2005-05-05 2006-11-09 Chroma Therapeutics Ltd Hydroxamic acid dervicatives as inhibitors of hdac enzymatic activity
US9133104B2 (en) 2005-05-05 2015-09-15 Chroma Therapeutics Ltd. Enzyme inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
US8093264B2 (en) 2005-05-20 2012-01-10 Methylgene Inc. Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
US8093295B2 (en) 2005-05-20 2012-01-10 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing the same
US8329726B2 (en) 2005-05-20 2012-12-11 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
US8450372B2 (en) 2005-05-20 2013-05-28 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8288440B2 (en) 2005-05-20 2012-10-16 Merck Sharp & Dohme Corp. Formulations of suberoylanilide hydroxamic acid and methods for producing same
US8158825B2 (en) 2005-06-24 2012-04-17 Merck Sharp & Dohme Corp. Modified malonate derivatives
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8188138B2 (en) 2005-09-21 2012-05-29 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
US8232297B2 (en) 2005-09-21 2012-07-31 4Sc Ag Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles
WO2007039404A1 (en) 2005-09-21 2007-04-12 Nycomed Gmbh Novel sulphonylpyrroles as inhibitors of hdac s novel sulphonylpyrroles
US8207202B2 (en) 2005-10-19 2012-06-26 Astrazeneca Ab Benzamide compounds useful as histone deacetylase inhibitors
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US7544695B2 (en) 2005-11-23 2009-06-09 Merck & Co., Inc. Spirocyclic compounds
US8686020B2 (en) 2005-11-23 2014-04-01 Merck Sharp & Dohme Corp. Spirocyclic compounds
US7834026B2 (en) 2005-11-23 2010-11-16 Merck Sharp & Dohme Corp. Spirocyclic compounds
US8349825B2 (en) 2005-11-23 2013-01-08 Merck Sharp & Dohme Corp. Spirocyclic compounds
US8759400B2 (en) 2005-12-19 2014-06-24 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
JP2009521424A (ja) * 2005-12-19 2009-06-04 メチルジーン インコーポレイテッド 抗真菌剤の活性を増強するためのヒストンデアセチラーゼ阻害剤
EP1963258A4 (en) * 2005-12-19 2011-06-29 Methylgene Inc HISTONE DEACETYLASE INHIBITORS FOR INCREASING THE ACTIVITY OF ANTIFUNGAL AGENTS
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8664223B2 (en) 2006-01-19 2014-03-04 Janssen Pharmaceutica N.V Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US9078896B2 (en) 2006-01-19 2015-07-14 Janssen Pharmaceutica, N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2007091703A1 (en) 2006-02-07 2007-08-16 Astellas Pharma Inc. N-hydroxyacrylamide compounds
US7750155B2 (en) 2006-02-07 2010-07-06 Astellas Pharma Inc. Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase
US8168658B2 (en) 2006-02-28 2012-05-01 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8119685B2 (en) 2006-04-26 2012-02-21 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
US8119652B2 (en) 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
WO2007143822A1 (en) * 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
US7981874B2 (en) 2006-07-20 2011-07-19 Merck Sharp & Dohme Corp. Phosphorus derivatives as histone deacetylase inhibitors
WO2008036046A1 (en) 2006-09-20 2008-03-27 S*Bio Pte Ltd IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
US8637547B2 (en) 2006-10-06 2014-01-28 Chroma Therapeutics Ltd. Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases
US9273003B2 (en) 2006-10-06 2016-03-01 Glaxosmithkline Intellectual Property Development Limited Methods of treating lymphoma and rheumatoid arthritis with cyclopentyl (2S)-cyclohexyl[({6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl}methyl)amino]acetate
EP2295410A1 (en) 2006-10-06 2011-03-16 Chroma Therapeutics Limited HDAC inhibitor
US9725407B2 (en) 2006-10-06 2017-08-08 Glaxosmithkline Intellectual Property Development Limited HDAC inhibitors
US8110577B2 (en) 2006-10-19 2012-02-07 Queen Mary & Westfield College Histone deacetylase inhibitors
EP2343286A1 (en) 2006-10-28 2011-07-13 Methylgene, Inc. Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase
EP2966078A2 (en) 2006-10-28 2016-01-13 MethylGene Inc. Inhibitors of histone deacetylase
WO2008055068A2 (en) 2006-10-28 2008-05-08 Methylgene Inc. Inhibitors of histone deacetylase
EP2489657A2 (en) 2006-10-28 2012-08-22 MethylGene Inc. Inhibitors of histone deacetylase
US8962825B2 (en) 2006-10-30 2015-02-24 Glaxosmithkline Intellectual Property Development Limited Hydroxamates as inhibitors of histone deacetylase
WO2008075757A1 (en) * 2006-12-15 2008-06-26 Astellas Pharma Inc. N-hydroxyacrylamide compounds
JP2010513326A (ja) * 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
JP2014111615A (ja) * 2006-12-19 2014-06-19 Methylgene Inc ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
AU2007335216B2 (en) * 2006-12-19 2013-08-15 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
AU2007335216C1 (en) * 2006-12-19 2014-07-10 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
EP2573069A3 (en) * 2006-12-19 2013-05-22 MethylGene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
WO2008074132A1 (en) * 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US9408816B2 (en) 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US9128096B2 (en) 2007-01-30 2015-09-08 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
US8030344B2 (en) 2007-03-13 2011-10-04 Methylgene Inc. Inhibitors of histone deacetylase
US8354445B2 (en) 2007-03-13 2013-01-15 Methylgene Inc. Inhibitors of histone deacetylase
US8461189B2 (en) 2007-06-27 2013-06-11 Merck Sharp & Dohme Corp. Pyridyl derivatives as histone deacetylase inhibitors
US9096559B2 (en) 2007-06-27 2015-08-04 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8008344B2 (en) 2007-09-14 2011-08-30 NatureWise Biotech and Medicals Corporation Compounds for the inhibition of histone deacetylase
WO2009037001A2 (en) 2007-09-19 2009-03-26 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
US8450525B2 (en) 2007-10-22 2013-05-28 Orchid Chemicals & Pharmaceuticals Limited Histone deacetylase inhibitors
EP2231596A4 (en) * 2007-12-14 2012-06-06 Univ Georgetown INHIBITORS OF HISTONATE ACETYLASE
US8293513B2 (en) 2007-12-14 2012-10-23 Georgetown University Histone deacetylase inhibitors
KR101198057B1 (ko) 2008-01-29 2012-11-07 에프. 호프만-라 로슈 아게 신규한 ｎ-(2-아미노-페닐)-아미드 유도체
WO2009095324A1 (en) * 2008-01-29 2009-08-06 F. Hoffmann-La Roche Ag Novel n-(2-amino-phenyl)-amide derivatives
US7795315B2 (en) 2008-01-29 2010-09-14 Hoffman-La Roche Inc. N-(2-amino-phenyl)-amide derivatives
EP2100882A1 (en) 2008-03-12 2009-09-16 4Sc Ag (E) -N -(2-Amino-phenyl) -3-{1-[4-(1-methyl-1H-pyrazol-4-yl)- benzenesulfonyl]-1H-pyrrol-3-yl} -acrylamide salts
CN110183425A (zh) * 2008-03-12 2019-08-30 4Sc股份公司 Hdac抑制剂
US7999000B2 (en) 2008-05-16 2011-08-16 Hoffmann-La Roche Inc. N-(2-amino-phenyl)-acrylamides
US9796664B2 (en) 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
EP2532657A2 (en) 2008-10-14 2012-12-12 Sunshine Lake Pharma Co., Ltd Compounds and methods of use
US7977372B2 (en) 2009-02-23 2011-07-12 Hoffmann-La Roche Inc. Ortho aminoamides for the treatment of cancer
WO2010097586A1 (en) 2009-02-27 2010-09-02 Chroma Therapeutics Ltd. Enzyme inhibitors
US9439877B2 (en) 2009-03-20 2016-09-13 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US9682919B2 (en) 2009-03-20 2017-06-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
US7994357B2 (en) 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2236503A1 (en) 2009-04-03 2010-10-06 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US10105552B2 (en) 2009-04-17 2018-10-23 Pharmacyclics Llc Formulations of histone deacetylase inhibitor and uses thereof
US9403032B2 (en) 2009-04-17 2016-08-02 Pharmacyclics Llc Formulations of histone deacetylase inhibitor and uses therof
CN102548975A (zh) * 2009-07-07 2012-07-04 安瑟生物科技私人有限公司 组蛋白去乙酰化酶抑制剂
EP2277387A1 (en) 2009-07-22 2011-01-26 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
US8841346B2 (en) 2009-10-30 2014-09-23 Massachusetts Institute Of Technology Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US8563615B2 (en) 2009-10-30 2013-10-22 Massachusetts Institute Of Technology Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders
US20180312455A1 (en) * 2011-02-10 2018-11-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury
US20140081054A1 (en) * 2011-02-10 2014-03-20 University of Pittsburgh - of the Commonwealth System of Higher Education, Pittsburgh, PA Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US10160705B2 (en) 2011-02-10 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US10626071B2 (en) 2011-02-10 2020-04-21 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2012109527A3 (en) * 2011-02-10 2012-10-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2012112447A3 (en) * 2011-02-14 2012-12-27 Dana-Farber Cancer Institute, Inc. Histone deacetylase inhibitors and methods of use thereof
US10301323B2 (en) 2011-02-28 2019-05-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9512143B2 (en) 2011-02-28 2016-12-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10280182B2 (en) 2011-02-28 2019-05-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
EP2680694A4 (en) * 2011-02-28 2014-09-03 Repligen Corp Histone deacetylase INHIBITORS
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10526346B2 (en) 2011-02-28 2020-01-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10981933B2 (en) 2011-02-28 2021-04-20 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
AU2012223509B2 (en) * 2011-02-28 2016-11-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9908899B2 (en) 2011-02-28 2018-03-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
WO2014022117A1 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
WO2014022116A2 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US10233201B2 (en) 2012-10-31 2019-03-19 University of Pittsburg—Of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
US9670236B2 (en) 2012-10-31 2017-06-06 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
EP3299019A1 (en) 2012-11-14 2018-03-28 Calitor Sciences, LLC Heteroaromatic compounds as pi3 kinase modulators and methods of use
WO2014130375A1 (en) 2013-02-21 2014-08-28 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10428028B2 (en) 2013-03-15 2019-10-01 Biomarin Pharmaceutical Inc. HDAC inhibitors
WO2014138989A1 (en) * 2013-03-15 2014-09-18 Methylgene Inc. Method and intermediates for the synthesis of hydroxamic acid compounds
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
EP3470536A1 (en) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
US9636298B2 (en) 2014-01-17 2017-05-02 Methylgene Inc. Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs
CN105237444A (zh) * 2015-09-24 2016-01-13 沈阳药科大学 异羟肟酸类化合物及其制备方法和用途
WO2017067447A1 (en) 2015-10-19 2017-04-27 Sunshine Lake Pharma Co., Ltd. A salt of egfr inhibitor, crystalline form and uses thereof
US10626092B2 (en) 2016-05-02 2020-04-21 Mei Pharma, Inc. Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereof
US11427544B2 (en) 2016-05-16 2022-08-30 Taipei Medical University Histone deacetylase 6 inhibitors and use thereof
CN109563046A (zh) * 2016-05-16 2019-04-02 Dcb-美国有限责任公司 组蛋白去乙酰酶6抑制剂及其用途
EP3484858A4 (en) * 2016-06-21 2020-02-26 The University of Melbourne HIV LATENCY ACTIVATORS
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2019063649A1 (en) 2017-09-27 2019-04-04 Onxeo COMBINATION OF A MOLECULE DBAIT AND AN HDAC INHIBITOR FOR THE TREATMENT OF CANCER
CN111072582A (zh) * 2018-10-18 2020-04-28 中国药科大学 一种n－羟基芳杂环－2－甲酰胺化合物及其制备方法和用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022018462A1 (en) * 2020-07-24 2022-01-27 University Of Newcastle Upon Tyne Catechol based derivatives for use in the prevention of dna damage
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
WO2025026925A1 (en) 2023-07-28 2025-02-06 Ospedale San Raffaele S.R.L. Gtf2i inhibitors and uses thereof

Also Published As

Publication number Publication date
EP1748046A2 (en) 2007-01-31
AU783504B2 (en) 2005-11-03
JP5290065B2 (ja) 2013-09-18
USRE39850E1 (en) 2007-09-18
JP2003514904A (ja) 2003-04-22
CA2391952C (en) 2012-01-31
JP2010013443A (ja) 2010-01-21
EP1748046A3 (en) 2007-08-22
EP1233958B1 (en) 2011-06-29
KR20100035666A (ko) 2010-04-05
CA2391952A1 (en) 2001-05-31
KR20070053362A (ko) 2007-05-23
KR20020070285A (ko) 2002-09-05
KR101026205B1 (ko) 2011-03-31
ATE514674T1 (de) 2011-07-15
KR20090007495A (ko) 2009-01-16
AU1876801A (en) 2001-06-04
DK1233958T3 (da) 2011-10-17
EP1233958A1 (en) 2002-08-28
PT1233958E (pt) 2011-09-20
USRE43343E1 (en) 2012-05-01
AU783504C (en) 2006-08-03
US6541661B1 (en) 2003-04-01
MXPA02005196A (es) 2003-09-22

Similar Documents

Publication Publication Date Title
AU783504C (en) Inhibitors of histone deacetylase
AU2007335216C1 (en) Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) Inhibitors of histone deacetylase and prodrugs thereof
JP5554988B2 (ja) ヒストンデアセチラーゼの阻害剤
US20020115826A1 (en) Inhibitors of histone deacetylase
HK1095043A (en) Inhibitors of histone deacetylase
AU2006200456A1 (en) Inhibitors of histone deacetylase
ES2368033T3 (es) Inhibidores de histona desacetilasa.
EP1524262A1 (en) Inhibitors of histone deacetylase
HK1181746A (en) Inhibitors of histone deacetylase and prodrugs thereof
HK1126769B (en) Benzamide derivatives as inhibitors of histone deacetylase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2391952

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027006560

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 540085

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005196

Country of ref document: MX

Ref document number: 18768/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000981535

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000981535

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027006560

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642